Summit Therapeutics Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Summit Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $227.41M.
- Summit Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $200.00M.
- Summit Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $0.00.
- Summit Therapeutics Inc. stock issued during period, value, new issues for fiscal 2022 was $99.89M, a 33.47% increase from fiscal 2021.
- Summit Therapeutics Inc. stock issued during period, value, new issues for fiscal 2021 was $74.84M, a 49.83% increase from fiscal 2020.
- Summit Therapeutics Inc. stock issued during period, value, new issues for fiscal 2020 was $49.95M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $227.41M 10-Q · filed 2026-07-23 | |
| 2024-06-30 | $200.00M 10-Q · filed 2024-08-06 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $499.38M derived: sum of 4 quarters · filed 2024-10-30 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $599.27M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $499.38M 10-Q · filed 2024-05-01 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $99.89M 10-K · filed 2024-02-20 |
| 2022-09-30 | $99.89M 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $74.84M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | |
| 2021-06-30 | $74.88M 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $49.95M 10-K/A · filed 2022-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |